000			02145 a2200601 4500
005			20250516060736.0
264		0	_c20121220
008			201212s 0 0 eng d
022			_a1536-4844
024	7		_a10.1002/ibd.21888 _2doi
040			_aNLM _beng _cNLM
100	1		_aVavricka, Stephan R
245	0	0	_aSystematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). _h[electronic resource]
260			_bInflammatory bowel diseases _cAug 2012
300			_a1523-30 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdalimumab
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAnti-Inflammatory Agents _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Humanized _xadministration & dosage
650	0	4	_aCertolizumab Pegol
650	0	4	_aCrohn Disease _xdrug therapy
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aImmunoglobulin Fab Fragments _xadministration & dosage
650	0	4	_aImmunosuppressive Agents _xtherapeutic use
650	0	4	_aInfliximab
650	0	4	_aInfusions, Intravenous
650	0	4	_aInjections, Subcutaneous
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPatient Preference
650	0	4	_aPolyethylene Glycols _xadministration & dosage
650	0	4	_aPrognosis
650	0	4	_aProspective Studies
650	0	4	_aSurveys and Questionnaires
650	0	4	_aTumor Necrosis Factor-alpha _xantagonists & inhibitors
650	0	4	_aYoung Adult
700	1		_aBentele, Nicoletta
700	1		_aScharl, Michael
700	1		_aRogler, Gerhard
700	1		_aZeitz, Jonas
700	1		_aFrei, Pascal
700	1		_aStraumann, Alex
700	1		_aBinek, Janek
700	1		_aSchoepfer, Alain M
700	1		_aFried, Michael
773	0		_tInflammatory bowel diseases _gvol. 18 _gno. 8 _gp. 1523-30
856	4	0	_uhttps://doi.org/10.1002/ibd.21888 _zAvailable from publisher's website
999			_c21221057 _d21221057